

ISSN 2355 - 8393

# FOLIA MEDICA INDONESIANA

Vol. 51 No. 4 October – December 2015

**BIOFILM BACTERIA PLAYS A ROLE IN CSOM PATHOGENESIS AND HAS SIGNIFICANT CORRELATION WITH UNSAFE TYPE CSOM**

(Antono, Nyiko Purnami, Rosyidah Rahmawati)

**SUB-ACUTE STENT THROMBOSIS AND IN-STENT RESTENOSIS ASSOCIATED WITH ANTIPLATELETS CLOPIDOGREL RESISTANCE AND PROTEIN S DEFICIENCY**

(M Zakky Kurniawan, Iswanto Pratana)

**EFFECT OF HYDROXYETHYL STARCH 200/0.5 ON VON WILLEBRAND FACTOR SERUM LEVEL AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)**

(Sarah Puspita Atmaja, Junaidi Khotib, Eddy Rahardjo, Dewi Wara Shinta, Mahardian Rahmadi, Budi Suprapti)

**THE USE OF HYDROXYETHYL STARCH 200/0.5 AS PLASMA SUBSTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL- $\beta$ -GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS**

(Dewi Wara Shinta, Junaidi Khotib, Eddy Rahardjo, Mahardian Rahmadi, Budi Suprapti)

**ETHANOL EXTRACT OF MANGOSTEEN PEEL REDUCES HISTOLOGICAL COUNT OF ALVEOLAR MACROPHAGE AND PULMONARY ALVEOLAR SPACE SIZE IN MALE WHITE RATS (*Rattus norvegicus*) EXPOSED TO CIGARETTE SMOKE**

(Anna Lewi Santoso)

**INJECTED CITICOLINE IMPROVES IMPAIRMENT AND DISABILITY DURING ACUTE PHASE TREATMENT IN ISCHEMIC STROKE PATIENTS**

(Rino Wahyudi, Didik Hasmono, Ruhaya Fitriana, Khairil Armal)

**PAPAYA SEED EXTRACT LOWERS SPERM CONCENTRATIONS, MOTILITY AND VIABILITY IN MALE MICE**

(Renyd Arindany Wiryawan, Reny I'tishom, Sri Purwaningsih)

**PCI IN PATIENT WITH HEAVY CALCIFIED LESION. MANAGEMENT AND BALLOON RUPTURE COMPLICATION**

(Yudi Her Oktaviano)

**EFFECTIVENESS OF *Betta splendens* AS A BIOLOGICAL PREDATORY AGAINST *Aedes aegypti* LARVAE**

(Saniya Hanum Permata, Subagyo Yotopranoto, Kusmartisnawati)

**CHARACTERISTICS OF HELLP SYNDROME IN SEVERE PREECLAMPSIA PATIENTS IN DR. SOETOMO HOSPITAL SURABAYA**

(Warth Angesti P, Ermawati, Dwi Susanti)

**CORRELATION OF HEARING IMPAIRMENT AND COMMUNICATION DISORDER AMONG GERIATRIC IN GERIATRIC CLINIC, DR. SOETOMO HOSPITAL SURABAYA**

(A Rama Kartika M, Nyiko Purnami, Paulus Liben)

**BARTHEL INDEX SCORE IN STROKE PATIENTS INCREASES AFTER UNDERGOING MEDICAL REHABILITATION**

(Sirly Nabireta Maharani Garing, Iham Subadi, Paulus Sugianto)

**NUTRITIONAL STATUS AFFECTS INCIDENCE OF PNEUMONIA IN UNDERFIVES**

(Henry Wicaksono)

International Online Distribution by ProQuest™  
www.proquest.com

Folia Medica Indonesiana	Vol. 51	No. 4	Page 208-291	Surabaya Oct-Dec 2015	ISSN 2355 - 8393
-----------------------------	---------	-------	--------------	--------------------------	---------------------

# FOLIA MEDICA INDONESIA

PUBLISHED BY  
THE CENTER FOR MEDICAL SCIENCE COMMUNITY  
FACULTY OF MEDICINE, UNIVERSITAS AIRLANGGA

p-issn 2355-8393  
e-ISSN 2599-056X  
Accredited no. 2/E/KPT/2015

HOME ABOUT LOGIN REGISTER SEARCH CURRENT ARCHIVES

Home > Archives > Vol 51, No 4 (2015)

## VOL 51, NO 4 (2015)

OKTOBER - DECEMBER 2015

### TABLE OF CONTENTS

#### ARTICLES

**BIOFILM BACTERIA PLAYS A ROLE IN CSOM PATHOGENESIS AND HAS SIGNIFICANT CORRELATION WITH UNSAFE TYPE CSOM**

PDF  
208-213

doi 10.20473/fmi.v51i4.2846

Abstract views = 313 times | PDF views = 403 times  
Artono Artono, Nyilo Purnami, Rosydiah Rahmawati

**SUB-ACUTE STENT THROMBOSIS AND IN-STENT RESTENOSIS ASSOCIATED WITH ANTIPLATELETS CLOPIDOGREL RESISTANCE AND PROTEIN S DEFICIENCY**

PDF  
214-220

doi 10.20473/fmi.v51i4.2949

Abstract views = 138 times | PDF views = 246 times  
M Zakky Kurniawan, Iswanto Pratanu

**EFFECT OF HYDROXYETHYL STARCH 200/0.5 ON VON WILLEBRAND FACTOR SERUM LEVEL AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)**

PDF  
221-227

doi 10.20473/fmi.v51i4.2848

Abstract views = 155 times | PDF views = 161 times  
Sarah Puspita Atmaja, Junaldi Khotib, Eddy Rahardjo, Dewi Wara Shinta, Mahardian Rahmadi, Budi Suprapti

**THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBSTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL-L-GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS**

PDF  
228-233

doi 10.20473/fmi.v51i4.2852

Abstract views = 125 times | PDF views = 127 times  
Dewi Wara Shinta, Junaldi Khotib, Eddy Rahardjo, Mahardian Rahmadi, Budi Suprapti

**ETHANOL EXTRACT OF MANGOSTEEN PEEL REDUCES HISTOLOGICAL COUNT OF ALVEOLAR MACROPHAGE AND PULMONARY ALVEOLAR SPACE SIZE IN MALE WHITE RATS (*Rattus norvegicus*) EXPOSED TO CIGARETTE SMOKE**

PDF  
234-244

doi 10.20473/fmi.v51i4.2853

Abstract views = 317 times | PDF views = 205 times  
Anna Lewi Santoso

**INJECTED CITICOLINE IMPROVES IMPAIRMENT AND DISABILITY DURING ACUTE PHASE TREATMENT IN ISCHEMIC STROKE PATIENTS**

PDF  
245-251

doi 10.20473/fmi.v51i4.2854

Abstract views = 220 times | PDF views = 409 times

#### Instruction for Author

Guidelines for Authors

Online Submission

Document Template

Disclaimer

#### Journal Policy

Focus and Scope

Publication Ethics

Article Processing Charge

Editorial Team

Peer Reviewers

Peer Review Process

Open Access Statement

Plagiarism Check

Archiving

Copyright

Contact

Old Website

#### OPEN JOURNAL SYSTEMS

#### Journal Help

#### USER

Username

Password

Remember me

Login

#### NOTIFICATIONS

View

Subscribe

#### JOURNAL CONTENT

Search

Search Scope

All

Search

Browse

By Issue

By Author

By Title

Other Journals

Rino Wahyudi, Didik Hasmono, Ruhaya Filtrina, Khairil Armal

**PAPAYA SEED EXTRACT LOWERS SPERM CONCENTRATIONS, MOTILITY AND VIABILITY IN MALE MICE**

PDF  
252-256

doi 10.20473/fmi.v51i4.2855

Abstract views = 186 times | views = 321 times

Reryd Arindany Wiryawan, Reny I'tishom, Sri Purwaningsih

**PCI IN PATIENT WITH HEAVY CALCIFIED LESION. MANAGEMENT AND BALLOON RUPTURE COMPLICATION**

PDF  
257-267

doi 10.20473/fmi.v51i4.2856

Abstract views = 291 times | views = 355 times

Yudi Her Oktaviono

**EFFECTIVENESS OF *Betta splendens* AS A BIOLOGICAL PREDATORY AGAINST *Aedes aegypti* LARVAE**

PDF  
268-271

doi 10.20473/fmi.v51i4.2857

Abstract views = 164 times | views = 216 times

Saniya Hanum Permata, Subagyo Yotopranoto, Kusmartisnawati Kusmartisnawati

**CHARACTERISTICS OF HELLP SYNDROME IN SEVERE PREECLAMPSIA PATIENTS IN DR. SOETOMO HOSPITAL SURABAYA**

doi 10.20473/fmi.v51i4.2858

Abstract views =

FONT SIZE

Visitors

ID 11,334	TH 140
US 1,816	MY 135
IN 270	AU 133
PH 171	TR 93
GB 165	SG 91

Pageviews: 67,077

FLAG counter

# FOLIA MEDICA INDONESIA

PUBLISHED BY  
THE CENTER FOR MEDICAL SCIENCE COMMUNITY  
FACULTY OF MEDICINE, UNIVERSITAS AIRLANGGA

p-issn 2355-8393  
e-ISSN 2599-056X  
Accredited no. 2/E/KPT/2015

[HOME](#) [ABOUT](#) [LOGIN](#) [REGISTER](#) [SEARCH](#) [CURRENT](#) [ARCHIVES](#)

[Home](#) > [About the Journal](#) > [People](#)

## PEOPLE

### PEER REVIEWERS

[Doddy M Soebadi](#), Department of Urology, Faculty of Medicine, Universitas Airlangga, Dr Soetomo Hospital, Surabaya, Indonesia, Indonesia

[Yukihiro Nishiyama](#), Nagoya University School of Medicine, Department of Virology, Nagoya, Japan

[Jaehyung Park](#), Seoul National University Hospital, Department of Radiology, Jongno-gu, Korea, Republic of

[Rika Yoshimatsu](#), Kochi University, Department of Radiology, Kochi, Japan

[Masaki Hara](#), Nagoya City West Medical Center, Department of Radiology, Nagoya, Japan

[Vanlila K Swami](#), Drexel University, Department of Pathology and Laboratory Medicine, Philadelphia, United States

[Yachen Shih](#), University of Texas M. D. Anderson Cancer Center, Section of Cancer Economics and Policy, Houston, United States

[Eiichi Konishi](#), Kyoto Prefectural University of Medicine, Department of Pathology, Kyoto, Japan

[Scott M Graham](#), University of Iowa Carver College of Medicine, Department of Otolaryngology-Head and Neck Surgery, United States

[Makito Okamoto](#), Kitasato University School of Medicine, Department of Otorhinolaryngology, Sagamiara, Japan

[Gayle O Fischer](#), Royal North Shore Hospital, Department of Dermatology, Sydney, Australia

[Peter Franz Riederer](#), Universitätsklinikum Würzburg, Department of Psychiatry, Würzburg, Germany

[Zachary A Knight](#), University of California System, Department of Physiology, Oakland, United States

[Juhan Kim](#), Seoul National University College of Medicine, Division of Biomedical Informatics, Seoul, Korea, Republic of

[Susanne MA Van Der Pol](#), VU University Medical Center, Department of Molecular Cell Biology and Immunology, Amsterdam, Netherlands

[Gustav A Drasch](#), Ludwig-Maximilians-Universität München, Department of Toxicology, Munich, Germany

[Augusto G Ferrari](#), IRCCS San Raffaele Scientific Institute, Department of Obstetrics and Gynecology, Milan, Italy

[Daniel Rossouw Franken](#), University of the Free State, Department of Obstetrics and Gynecology, Bloemfontein, South Africa

[Antonio Farina](#), Alma Mater Studiorum Università di Bologna, Department of Obstetrics and Prenatal Medicine, Bologna, Italy

[Keith Phillip George](#), Liverpool John Moores University, Research Institute for Sport and Exercise Sciences, Liverpool, United Kingdom

[Archana VN Swami](#), Harvard School of Public Health, Department of Environmental Health, Boston, United States

[Atsushi Goto](#), Tokyo Women's Medical University, Department of Public Health, Tokyo, Japan

[Shunichi Shimizu](#), Teikyo Heisei University, Division of Pharmacology, Ichihara, Japan

[Liao Cui](#), Research and Development of Natural Drugs, Guangdong Key Laboratory, Zhanjiang, China

[Paul G Thomas](#), St. Jude Children Research Hospital, Department of Immunology, Memphis TN, United States

[Gabriele Roeder](#), Ludwig-Maximilians-Universität München, Institute of Forensic Medicine, Munich, Germany

### Instruction for Author

[Guidelines for Authors](#)

[Online Submission](#)

[Document Template](#)

[Disclaimer](#)

### Journal Policy

[Focus and Scope](#)

[Publication Ethics](#)

[Article Processing Charge](#)

[Editorial Team](#)

[Peer Reviewers](#)

[Peer Review Process](#)

[Open Access Statement](#)

[Plagiarism Check](#)

[Archiving](#)

[Copyright](#)

[Contact](#)

[Old Website](#)

### OPEN JOURNAL SYSTEMS

#### Journal Help

#### USER

Username

Password

Remember me

#### NOTIFICATIONS

[View](#)

[Subscribe](#)

#### JOURNAL CONTENT

Search

Search Scope

All

Browse

[By Issue](#)

[By Author](#)

[By Title](#)

[Other Journals](#)

- Shoji Ohno, International University of Health Science, Department of Cardiology, Toronto, Canada
- Talha A Farid, THFCFM Laboratory, Department of Cardiology, Toronto, Canada
- Yoshiaki Sugimura, Mie University School of Medicine, Department of Nephro-Urologic Surgery and Andrology, Tsu, Japan
- Jutta Marfurt, Menzies School of Health Research, Global and Tropical Health Division, Casuarina, Australia
- Jiro Arikawa, Hokkaido University School of Medicine, Department of Microbiology, Sapporo, Japan
- Gerhard R Pierer, Medizinische Universität Innsbruck, Department of Plastic Surgery, Innsbruck, Austria
- Akiyoshi Hirano, Nagasaki University School of Medicine, Department of Plastic and Reconstructive Surgery, Nagasaki, Japan
- Keiji Kawamoto, Kansai Medical University, Department of Neurosurgery, Moriguchi, Japan
- Shinjiro Sasaki, Osaka Medical College, Department of Cardiothoracic Surgery, Takatsuki, Japan
- Jeffrey S Upperman, Children's Hospital Los Angeles, Division of Pediatric Surgery, Los Angeles, United States
- Masanobu Ohishi, Kyushu University, Department of Orthopaedic Surgery, Fukuoka, Japan
- Udom Kachintorn, Mahidol University, Department of Internal Medicine, Nakhon Pathom, Thailand
- A Barac, Washington Hospital Center, MedStar Heart and Vascular Institute, Washington, United States
- Kumaralingam G Balakrishnan, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Department of Cardiology, Thiruvananthapuram, India
- Christina E West E West, Umea Universitet, Department of Clinical Sciences/Pediatrics, Umea, Sweden
- Pagakrong Lumbiganon, Khon Kaen University, Department of Pediatrics, Khon Kaen, Thailand
- Önder Arslan, Istanbul Tıp Fakültesi, Department of Hematology, Istanbul, Turkey
- Satoru Shimizu, Yokohama Brain and Spine center, Department of Neurosurgery, Isogo-ku, Yokohama, Kanagawa Prefecture, Japan
- Sheng Fung Lin, Kaohsiung Medical University Chung-Ho Memorial Hospital, Department of Internal Medicine, Kaohsiung, Taiwan, Province of China
- Hyojin Park, Yonsei University College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of
- Hiroaki Kimura, Department of Physical Medicine and Rehabilitation, Hiroshima University Hospital, Japan
- Kuntaman Kuntaman, Universitas Airlangga, Indonesia
- Iswan A Nusi, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
- Muhammad Husein Gasem, Center for Tropical and Infectious Diseases (CENTRID), Universitas Diponegoro, Semarang, Indonesia
- Bambang Hariwiyanto, Department of Otolaryngology-Head and Neck Surgery, Gadjah Mada University, Yogyakarta, Indonesia
- Suharyo Hadisaputro, Department of Public Health, Universitas Diponegoro, Semarang, Indonesia
- Zainal Arifin Adnan, Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia



Universitas Airlangga  
copyright © 2017 Template PPJPI

**FONT SIZE**

---

**Visitors**

 ID 11,341	 TH 140
 US 1,816	 MY 135
 IN 270	 AU 133
 PH 171	 TR 93
 GB 165	 SG 91

Pageviews: 67,166

 FLAG counter



00082654

[View My Stats](#)

# FOLIA MEDICA INDONESIA

PUBLISHED BY  
THE CENTER FOR MEDICAL SCIENCE COMMUNITY  
FACULTY OF MEDICINE, UNIVERSITAS AIRLANGGA

p-issn 2355-8393  
e-ISSN 2599-056X  
Accredited no. 2/E/KPT/2015

HOME ABOUT LOGIN REGISTER SEARCH CURRENT ARCHIVES

Home > Vol 51, No 4 (2015) > **Atmaja**



## EFFECT OF HYDROXYETHYL STARCH 200/0.5 ON VON WILLEBRAND FACTOR SERUM LEVEL AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

Sarah Puspita Atmaja, Junaidi Khotib, Eddy Rahardjo, Dewi Wara Shinta, Mahardian Rahmadi, Budi Suprpti



doi = <http://dx.doi.org/10.20473/fmi.v51i4.2848>

Abstract views = 155 times | views = 161 times

### ABSTRACT

Hydroxyethyl starch (HES) is a colloid administered frequently for intravascular volume expansion during perioperative period. Impairment of haemostasis have been reported during HES administration, but the volume of solution administered was usually higher than 20 ml.kg<sup>-1</sup>. The objective of this study was to evaluate the effect of Hydroxyethyl starch 200/0.5 dose less than 20 ml.kg<sup>-1</sup> on von Willebrand factor serum level and activated partial thromboplastin time. A prospective, observational study was conducted to evaluate von Willebrand factor and activated partial thromboplastin time of patients receiving Hydroxyethyl starch 200/0.5. Inclusion criteria were patients undergoing elective surgery who were going to receive Hydroxyethyl starch 200/0.5 intraoperatively. Fourty six patients were divided into patients receiving crystalloid only group (n=23 patients) and hydroxyethyl starch (n=23 patients). Coagulation variables were assesed 30 minute after insicion and 60 minute after infuson of crystalloid or colloid. Measurement of von Willebrand within each group after crystalloid or HES 200 infusion showed significant decrease, from (mean±SE) 97.688±15.219 ng/ml to 31.611±10.058 ng/ml (p< 0.001) in crystalloid group and 92.884±15.208 ng/ml to 27.378±6.399 ng/ml (p<0.001) in HES 200 group. Activated partial thromboplastin time change was statistically significant (mean±SE) 31.27±1.39 to 35.61±1.62 in HES group only (p=0.007), but this change was not clinically significant. In conclusion, there was neither significant difference in von Willebrand serum level nor in activated partial thromboplastin time between the two groups. There was no coagulation influence with clinically significant effect in the use of HES 20 ml/kg BW in patients undergoing elective surgery.

### KEYWORDS

hydroxyethyl starch 200/0.5, coagulation impairment, von Willebrand factor serum level, activated partial thrombopalsin time

### FULL TEXT:



### REFERENCES

- Boldt J (2008). Fluid choice for resuscitation in trauma. *International Trauma Care* 18, 57-65
- Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV (2013). Clearance of von Willebrand factor. *J Thromb Haemost* 11 Suppl 1, 202-211
- Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, Webb AR (1994). The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. *Intensive Care Med* 20, 37-41
- de Jonge E, Levi M, Büller HR, Berends F, Kesecioglu J (2001). Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. *Intensive Care Med* 27, 1825-1829
- Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, Ingerslev J, Sørensen B (2009). Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. *J Thromb Haemost* 7, 795-802
- Gabali A, Jazearly T, Ramchandren R, Bluth MH (2014). Applications of coagulation testing and methodology in the trauma patient. *Research and Reviews: Journal of Medical and Health Sciences* 3, 1-4

#### Instruction for Author

Guidelines for Authors

Online Submission

Document Template

Disclaimer

#### Journal Policy

Focus and Scope

Publication Ethics

Article Processing Charge

Editorial Team

Peer Reviewers

Peer Review Process

Open Access Statement

Plagiarism Check

Archiving

Copyright

Contact

Old Website

#### OPEN JOURNAL SYSTEMS

#### Journal Help

#### USER

Username

Password

Remember me

Login

#### NOTIFICATIONS

View  
Subscribe

#### JOURNAL CONTENT

Search

Search Scope

All

Search

Browse

By Issue

By Author

By Title

Other Journals

Gan TJ (2011). Colloid or crystalloid: any differences in outcomes? IARS Review Course Lectures, 7-12

Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Malzel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012). Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. *Crit Care* 16, R94

Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, Oswald E, Salner E, Frischhut B, Schoberberger W (2002). The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. *Anesth Analg* 95, 858-865

Kamal AH, Tefferi A, Pruthi RK (2007). How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. *Mayo Clin Proc* 82, 864-873

Kozek-Langenecker SA, Jungheinrich C, Saueremann W, Van der Linden P (2008). The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. *Anesth Analg* 107, 382-390

Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P (2001). Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. *Anesth Analg* 92, 855-862

Lenting PJ, Christophe OD, Denis CV (2015). von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. *Blood* 125, 2019-2028

Mills GH (2007). Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? *Br J Anaesth* 98, 157-159

Muralidhar K, Garg R, Mohanty S, Banakal S (2010). Influence of colloid infusion on coagulation during off-pump coronary artery bypass grafting. *Indian J Anaesth* 54, 147-153

Myburgh JA and Mythen MG (2013). Resuscitation fluids. *The New England Journal of Medicine* 369, 1243-1251

Ng KF, Lam CC, Chan LC (2002). In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. *Br J Anaesth* 88, 475-480

Peyvandi F, Garagiola I, Baronciani L (2011). Role of von Willebrand factor in the haemostasis. *Blood Transfus* 9, s3-s8

Reininger AJ (2008). Function of von Willebrand factor in haemostasis and thrombosis. *Haemophilia* 14, 11-26

Rittoo D, Gosling P, Simms MH, Smith SR, Vohra RK (2005). The effects of hydroxyethyl starch compared with gelofusine on activated endothelium and the systemic inflammatory response following aortic aneurysm repair. *Eur J Vasc Endovasc Surg* 30, 520-524

Ruttman TG, James MF, Finlayson J (2002). Effects on coagulation of intravenous crystalloid or colloid in patients undergoing peripheral vascular surgery. *Br J Anaesth* 89, 226-230

Sadler JE (2009). Low von Willebrand factor: sometimes a risk factor and sometimes a disease. *Hematology Am Soc Hematol Educ Program*, 106-112

Wilson DD (2007). *McGraw-Hill Manual of Laboratory and Diagnostic Tests 1st Edition*, New York, McGraw-Hill Education

## REFBACKS

- There are currently no refbacks.

Copyright (c) 2016 Folia Medica Indonesiana



00082552

[View My Stats](#)



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#)

FONT SIZE

## Visitors

ID 11,334	TH 140
US 1,816	MY 135
IN 270	AU 133
PH 171	TR 93
GB 165	SG 91

Pageviews: 67,074



## EFFECT OF HYDROXYETHYL STARCH 200/0.5 ON VON WILLEBRAND FACTOR SERUM LEVEL AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

Sarah Puspita Atmaja<sup>1</sup>, Junaidi Khotib<sup>1</sup>, Eddy Rahardjo<sup>2</sup>, Dewi Wara Shinta<sup>1</sup>, Mahardian Rahmadi<sup>1</sup>, Budi Suprapti<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University

<sup>2</sup>Department of Anesthesiology and Reanimation, Faculty of Pharmacy, Airlangga University

### ABSTRAK

Hydroxyethyl starch (HES) merupakan koloid yang sering digunakan sebagai plasma ekspander selama periode operasi. Beberapa gangguan haemostasis sudah dilaporkan akibat penggunaan HES, namun volume HES yang diberikan lebih dari 20 ml/kgBB. Tujuan penelitian ini adalah untuk mengevaluasi pengaruh Hydroxyethyl starch 200/0,5 dengan dosis kurang dari 20 ml/ kg BB terhadap kadar faktor von Willebrand dan activated partial thromboplastin time. Penelitian dilakukan dengan metode prospektif observasional. Kriteria inklusi penelitian ini adalah pasien yang menjalani operasi elektif yang mendapat HES 200/0,5 selama operasi. Empat puluh enam pasien dibagi menjadi dua kelompok yaitu kelompok pasien yang hanya mendapatkan cairan kristaloid (n=23 pasien) dan HES (n=23 pasien). Koagulasi diperiksa 30 menit setelah insisi dan 60 menit setelah pemberian kristaloid atau koloid. Penurunan yang signifikan pada kadar faktor von Willebrand didapatkan pada kedua kelompok. Didapatkan penurunan dari (mean±SE) 97,688±15,219 ng/ml menjadi 31,611±10,058 ng/ml (p< 0,001) pada kelompok kristaloid dan 92,884±15,208 ng/ml menjadi 27,378±6,399 ng/ml (p<0,001) pada kelompok HES 200. Perubahan signifikan activated partial thromboplastin time hanya terjadi pada kelompok HES 200 dari (mean±SE) 31,27±1,39 menjadi 35,61±1,62 (p=0.007). Namun perubahan ini tidak signifikan secara klinis. Sebagai simpulan, tidak terdapat perbedaan yang signifikan antara kedua kelompok cairan pada kadar faktor von Willebrand atau APTT. Tidak terdapat pengaruh koagulasi yang memberikan efek klinik yang signifikan pada penggunaan HES 20 ml/kg BB selama pasien menjalani operasi elektif. (FMI 2015;51:221-227)

**Kata kunci:** hydroxyethyl starch 200/0,5, kadar faktor von Willebrand factor, activated partial thromboplastin time

### ABSTRACT

Hydroxyethyl starch (HES) is a colloid administered frequently for intravascular volume expansion during perioperative period. Impairment of haemostasis have been reported during HES administration, but the volume of solution administered was usually higher than 20 ml.kg<sup>-1</sup>. The objective of this study was to evaluate the effect of Hydroxyethyl starch 200/0.5 dose less than 20 ml.kg<sup>-1</sup> on von Willebrand factor serum level and activated partial thromboplastin time. A prospective, observational study was conducted to evaluate von Willebrand factor and activated partial thromboplastin time of patients receiving Hydroxyethyl starch 200/0.5. Inclusion criteria were patients undergoing elective surgery who were going to receive Hydroxyethyl starch 200/0.5 intraoperatively. Forty six patients were divided into patients receiving crystalloid only group (n=23 patients) and hydroxyethyl starch (n=23 patients). Coagulation variables were assessed 30 minute after incision and 60 minute after infusion of crystalloid or colloid. Measurement of von Willebrand within each group after crystalloid or HES 200 infusion showed significant decrease, from (mean±SE) 97.688±15.219 ng/ml to 31.611±10.058 ng/ml (p< 0.001) in crystalloid group and 92.884±15.208 ng/ml to 27.378±6.399 ng/ml (p<0.001) in HES 200 group. Activated partial thromboplastin time change was statistically significant (mean±SE) 31.27±1.39 to 35.61±1.62 in HES group only (p=0.007), but this change was not clinically significant. In conclusion, there was neither significant difference in von Willebrand serum level nor in activated partial thromboplastin time between the two groups. There was no coagulation influence with clinically significant effect in the use of HES 20 ml/kg BW in patients undergoing elective surgery. (FMI 2015;51:221-227)

**Keywords:** hydroxyethyl starch 200/0.5, coagulation impairment, von Willebrand factor serum level, activated partial thromboplastin time

**Correspondence:** Sarah Puspita Atmaja, Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia. Email: sarahpuspita.pharmacist@gmail.com

### INTRODUCTION

Hydroxyethyl starch (HES) is widely used as a plasma substitute in bleeding during surgery. HES is a synthesis

of amylopectin with hydroxyethyl substitution by ethylene oxide at position C2 and C6 which is able to slow down enzymatic degradation by amylase, thereby extending its intravascular shelf life (Mills 2007, Gan



2011, Myburgh & Mythen 2013). To achieve hemodynamic stability, HES requires less volume than NaCl (Guidet et al 2012).

The influence of HES 200/0.5 use in decreasing levels of von Willebrand factor was observed in healthy volunteers (de Jonge et al 2001). Whereas, study on surgery patients who used HES 200/0.5 during the operation at a dose of  $2.104 \pm 622$  showed significant APTT prolongation and decreased levels of von Willebrand factor in the group receiving HES 200/0.5, and that blood loss and the need for blood transfusions were significantly more common in patients using HES 200/0.5 (Kozek-Langenecker et al 2008).

The effect of HES on blood coagulation function in subjects in Indonesia has not been studied. This study examined the effect of HES on blood coagulation based on HES doses in Dr Soetomo Hospital, which was as much as 10-20 ml/kg during surgery. This study aimed to evaluate the effect of hydroxyethyl starch as fluid resuscitation in patients who have bleeding during surgery on von Willebrand factor level and activated partial thromboplastin time (APTT).

## MATERIALS AND METHODS

This study used prospective observational design with sample of patients undergoing elective surgery in Gedung Bedah Pusat Terpadu (GBPT), Dr. Soetomo Hospital, Surabaya, and required crystalloid resuscitation therapy as a control group and HES as treatment group included in inclusion and exclusion criteria. The inclusion criteria were age 18-50 years; patients undergoing elective surgery with a maximum bleeding of 20% EBV who received crystalloid resuscitation or HES 200/0.5, willing to sign the informed consent, patients with coagulation function (PT <13 APTT <33 seconds), renal or hepatic function (serum creatinine <1.2 mg/dL, alanine amino transferase <90 mg/dl, or aspartate amino transferase <70 mg/dl); and patients with Hb > 10g/dl. Exclusion criteria for the study were patients who received warfarin, heparin or low molecular weight heparin, clopidogrel or for 5 days before surgery, patients receiving oral contraceptives, and long term use of corticosteroids.

Subjects were divided into two groups: crystalloid and HES 200 groups. Both groups received crystalloid as maintenance fluid to overcome the loss of fluids through urine, gastrointestinal and respiratory during operation. The choice of the fluid depends on the bleeding condition of each patient.

Blood samples were taken twice, initial for baseline level, 30 minutes after the incision, and 60 minutes after the fluid was given. Of the samples obtained, the activated partial thromboplastin time (APTT) and von Willebrand factor level was measured using von Willebrand antigen (vWF: ag) with ELISA method of Elabscience.

Data obtained were in the form of means  $\pm$  SE. Shapiro-Wilk test was used to test data normality. Comparative test for pre- and post von Willebrand factor levels and APTT in each group was done using paired t-test when the distribution was normal, and Wilcoxon test if the distribution was not normal. As for comparing the value of the parameter in the patients receiving HES and patients who did not use HES (controls) we used ANCOVA with covariat bleeding (% EBV) if the data were homogeneous and linear regression test if the data were not homogeneous.

To show the effect of plasma dilution by HES or crystalloid, we made the calculation according to the formula  $D = Hb/Hb_0 \times (1-Ht_0)/(1-Ht)$ , in which D: dilution factor; Hb<sub>0</sub>, Ht<sub>0</sub>: hemoglobin and hematocrit concentration prior to infusion fluids; and Hb, Ht: hemoglobin and hematocrit concentrations after fluid infusion. Subsequently, the concentration of von Willebrand factor in plasma after dilution was calculated using formula  $C = C_0 \times D$ , with C<sub>0</sub>: concentration before dilution; C: concentration after dilution; D: dilution factor. Statistical calculations of independent t-test was used to compare the calculation levels of von Willebrand factor from baseline and after fluid infusion in each group.

## RESULTS

A total of 46 patients involved in this study were divided into two groups, the group of patients who only received crystalloid and a group of patients who received crystalloid and HES 200. From the data on patients characteristics involved in this study and the amount of resuscitation fluid provided during the observation, there were no significant differences between the two groups (Table 1 and Table 3). However, there was significant difference as for the bleeding volume occurred during surgery between the two groups (Table 2). vWF levels in blood decreased significantly in both groups ( $p < 0.001$ ). However, when compared the difference of vWF:ag between both groups, there was no significant difference ( $p = 0.486$ ). When compared with calculations using dilution factor (Table 5), the decrease of vWF in each group showed significant difference ( $p < 0.001$ ) (Figure 1).

Table 1. Characteristics of patients involved in the study

Parameters	Crystalloid (n=23)	HES 200 (n=23)	P values
Ages (years)	43.39±11.54	46.60±9.12	p=0.061
Creatinin serum (mg/dl)	0.72±0.19	0.78±0.20	p=0.350
APTT (sec)	29.17±5.52	27.8±5.34	p=0.428
SGOT (mg/dl)	19.21±10.51	18.85±13.36	p=0.925
SGPT (mg/dl)	22.26±10.15	19.61±11.08	p=0.436
Hb (g/dl)	12.5±1.26	12.09±1.48	p=0.309

Table 2. Total bleeding volume in crystalloid and HES 200 groups during operation

	Crystalloid group (mean±SD)	HES 200 group (mean±SD)	P value
Bleeding (%EBV)	9.04±4.37	15.77±5.97	<0.001**

\*\*Coagulation studies

Table 3. Total fluid received by patients in crystalloid and HES 200 groups

	Crystalloid group (mean±SE)	HES 200 group (mean±SE)	P value
Total administered fluid	Crystalloid : 1113.04±96.490	Crystalloid : 1249.13±79.404 HES : 507±45.70 ml	0.282




Figure 1. Changes in the levels of von Willebrand factor in crystalloid and HES 200 groups

Table 4. Comparative test pre and post of von Willebrand factor levels in crystalloid and HES 200 groups

Groups	n	pre mean±SE.	post mean±SE.	Comparison mean±SE.	P value
Crystalloid	23	97.688±15.219	31.611±10.058	-66.086±14.677	< 0.001**
HES 200	23	92.884±15.208	27.378±6.399	-65.934±13.757	< 0.001**

\*\*Coagulation studies

Table 5. Comparison of calculated von Willebrand factor levels and measured von Willebrand factor levels

Fluid groups	Calculated vWF level $\pm$ SD	Measured vWF level $\pm$ SD	P value
Crystalloid	93.97 $\pm$ 7.36	27.37 $\pm$ 3.06	<0.001**
HES 200	96.72 $\pm$ 7.45	31.61 $\pm$ 4.83	<0.001**

\*\*Coagulation studies




Figure 2. Changes in APTT in crystalloid and HES 200 groups

Table 6. Comparison of pre and post APTT in in crystalloid and HES 200 groups

	n	pre mean $\pm$ SE	post mean $\pm$ SE	Comparison mean $\pm$ SE	P value
Crystalloid	23	31.87 $\pm$ 1.63	31.33 $\pm$ 1.60	0.54 $\pm$ 0.81	0.510
HES 200	23	31.27 $\pm$ 1.39	35.61 $\pm$ 1.62	4.33 $\pm$ 1.46	0.007**

APTT results in each group showed no significant change (Figure 2), as we also see if we compared the APTT difference between both groups ( $p = 0.654$ )

## DISCUSSION

The focus of this study was on the effect of HES 200 administration on the alteration of von Willebrand factor level. Statistical analysis (Table 4) revealed that the level of von Willebrand factor either in cristalloid or HES 2000 groups showed significant reduction, with a slight higher mean in cristalloid group compared to that in HES 2000 group (66.086 $\pm$ 14.677 vs 65.934 $\pm$ 13.757). Characteristics of total bleeding between both groups also showed significant difference (Table 2). In cristal-

loid group, the %EBV was 9.04 $\pm$ 4.37, while that in HES 2000 group was 15.77 $\pm$ 5.97. This finding raised question whether such difference in total bleeding may affect difference of von Willbrand factor reduction. Therefore, to compare this difference between patients receiving cristalloid and those receiving HES 2000, we used multivariate analysis with linear regression test. The test revealed no significant difference (Figure 2) between both groups with  $p=0.486$ .

The reduction in each group (Table 4) lead to von Willebrand factor level of 31.611 $\pm$ 10.058 ng/ml in cristalloid group and 27.378 $\pm$ 6.499 ng/ml in HES 200 group. Sadler (2009) suggested that the reduction of vol Willebrand factor of 30-50 ng/ml has intermediate bleeding risk. However, this study has limiation since it

did not evaluate further, whether the reduction of Willebrand factor due to HES 200 administration continues.

Decreased levels of von Willebrand factor in crystalloid and HES 200 groups in this study confirmed previous study by Innerhofer et al (2002) in 60 patients undergoing orthopedic surgery. The study found significant decrease of von Willebrand factor is in Ringer Lactate group ( $4801 \pm 1239$  ml) from 130% to 121% and in HES group 200 ( $1242 \pm 315$  ml) from 128% to 118%, which was observed before and after surgery. The study did not find difference in significant decrease in von Willebrand factor between Ringer's lactate and HES 200 groups. Declining levels of von Willebrand factor was also found by Muralldhar (2010) in a study of patients undergoing coronary artery bypass. In that study, most significant vWF levels decrease was found after the administration of 7-8 ml/kg HES 200. However, 24 hours after the operation, von Willebrand factor levels rose again, approaching baseline levels.

In physiological conditions, the elimination of von Willebrand factor is carried out by the liver and spleen. Macrophages are a type of cells that play the most predominant role in two organs in the process of von Willebrand factor elimination. Receptors that have been identified to play a role in mediating vWF factor endocytosis in macrophages is a lipoprotein receptor (LPR1) and Siglec-5. The half-life of von Willebrand factor in circulation is 16 hours. In this study, sampling point after HES 200 administration was 60 minutes. Therefore, the decline of HES 200 in this study was not influenced by vWF factor half-life in blood circulation (Casari et al 2013, Lenting et al 2014).

In this study, von Willebrand factor decrease was not only due to the dilution, as confirmed by calculation of the plasma dilution factor. Results of calculations with dilution factor was compared with post-treatment von Willebrand factor in each fluid group. If the results of the comparative test showed significant difference, it can be concluded that the decrease of von Willebrand factor is not only the result of dilution. From comparative test results (Table 5) using the Mann-Whitney test there were significant differences in each group ( $p = 0.000$ ) for crystalloid and HES 200 groups.

Mechanisms that could explain how the influence of hydroxyethyl starch can reduce von Willebrand factor cannot be confirmed. An in vitro study conducted by Collis et al (1994), observing the influence of hydroxyethyl starch on endothelial cells activity in culture, showed that there was inhibition of von Willebrand factor release, which comprised adhesion molecules

stored in endothelial cells in group receiving HES. This resulted in significant decreased of von Willebrand factor ( $p = 0.01$ ) compared to other plasma substitution fluids. This is supported by a study by Ritto et al (2005), who compared the effect of hydroxyethyl starch with gelofusin in patients with abdominal aortic aneurysm repair. Decreased level of von Willebrand factor was obtained in two groups at the beginning before the opening of the aortic clamp abdominal. The reduction indicates acute phase of response proteins in circulation, resulting in increased consumption of vWF factor.

Furthermore, after the clamp was opened vWF factor increased in gelofusin group from 110 U/dL to 173.5 U/dl, showing a continued release of vWF by endothelial activation, whereas in the HES group decreased from 96.5 U/dl to 80.5 U/dl. This indicates that after initial endothelial activation, HES affected the stabilization of effects of endothelium. The finding that improved endothelial stabilization results from HES influence is supported by a study by Boldt et al (2003). This study did not use vWF factor as parameter. Instead, it used adhesion molecules released in the circulation, the endothelial leukocyte adhesion molecule-1 (ELAM-1) and intercellular adhesion molecule-1 (ICAM-1), that may reflect the activation of endothelial cells. This study found an increase of both adhesion molecules which was higher in crystalloid group compared to that in HES group ( $p = 0.05$ ). This demonstrates that the HES has a stabilizing effect on endothelial cells by stabilizing fragile cell membranes, so that it reduces its activity in releasing of adhesion molecules. However, we are still unable to explain the mechanism of vWF factor reduction in the group of patients receiving crystalloid fluids alone.

In this study, vWF factor reduction in HES group was followed by prolonged APTT time (Table 6) from  $31.27 \pm 1.39$  to  $35.61 \pm 1.62$  ( $p = 0.007$ ). In crystalloid group von Willebrand factor decreased from  $97.688 \pm 15.219$  ng/ml to  $31.611 \pm 10.058$  ng/ml (Table 4), but was not followed by statistically significant changes in APTT (Table 6). Comparative analysis of APTT difference between patients receiving crystalloid solution and those receiving HES 200 was done using ANCOVA statistical test. The result showed no significant differences between both groups with  $p = 0.654$  (Figure 2). Other studies in healthy volunteers and in surgery patients by Langeron et al (2001) and de Jonge et al (2001) showed significant prolonged APTT in patients receiving HES 200 fluid. Insignificant APTT alteration in crystalloid and HES 200 groups was also obtained a study by Rutmann et al (2002). Increased APTT in HES group was  $4.33 \pm 7.04$  seconds of normal value. Although it is significant statistically, clinically it is not, since clinically pathological increase of APTT is the increase

as many as 1.5-2.5 times that of control value (Wilson 2008).

Decreased levels of von Willebrand factor in each group, as seen in Figure 1, shows decreased levels of von Willebrand factor in patients receiving HES 200 fluid. In addition to HES 200, this group also received crystalloid and showed decreased von Willebrand factor that was not significantly different from that of patients who received crystalloid fluids alone. Similarly, APTT alteration (as seen in Figure 2) shows that HES 200 administration in bleeding patients, reaching averagely 15% EBV with maximum dose of HES 200 of 20 ml/kg, could still be regarded as clinically safe.

Prolonged APTT time in HES 200 use indirectly resulted from decreased vWF factor. In domain D of vWF structure, there is the site of blood clotting factor VIII binding, while the factor VIII itself belongs to intrinsic pathway of blood coagulation. Prolonged APTT time may result from reduced blood clotting factors in the intrinsic pathway, one of which is the factor VIII (Kamal et al 2007, Reininger 2008, Gabali et al 2014). Von Willebrand factor reduction in circulation caused by HES use affects the decrease of factor VIII concentration because vWF has a function to maintain the stability of factor VIII. Binding form of vWF-VIII protects factor VIII from degradation of protein C (Peyvandi 2011). Therefore, reduced levels of vWF factor in circulation will be followed by decreased levels of factor VIII since a large number of factors VIII being degraded by protein C. A study by Langeron et al (2001) and Innerhofer et al (2002) showed a significant decrease in vWF factor followed by decreased levels of factor VIII in the use of HES 200.

According to Wilson (2008), prolonged APTT is not only caused by decreased levels of factor VIII, but also be affected by the decreased of other factors' levels, the factor I, II, V, IX, X, XI, and XII. Therefore, in this study prolonged APTT in a group of patients receiving HES 200 was not only due to decreased levels of factor VIII as described above, but could also be due to decreased levels of other factors, as has been proved a study by Fenger-Eriksen et al (2009). However, this study did not observe other coagulation factors.

As to the use of crystalloid, there was no change in APTT. This may be explained from in vivo study on hepatobiliary surgery patients conducted by Ng et al (2002) who found decreased levels of antithrombin III and protein C in hemodilution by normal saline. Antithrombin III is the most potent inhibitors that inhibit the intrinsic factor IXa, Xa, X<sub>ia</sub> and XIIa, while protein C has functions in the degradation of factor VIII, which enables a decrease in antithrombin III and protein C

since the use of crystalloid is still going to be a factor in the coagulation process.

## CONCLUSION

HES 200 in a maximum dose of 20 ml/kg is safe for use in elective surgery patients who experience bleeding of averagely 15% EBV.

## REFERENCES

- Boldt J (2008). Fluid choice for resuscitation in trauma. *International Trauma Care* 18, 57-65
- Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV (2013). Clearance of von Willebrand factor. *J Thromb Haemost* 11 Suppl 1, 202-211
- Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, Webb AR (1994). The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. *Intensive Care Med* 20, 37-41
- de Jonge E, Levi M, Büller HR, Berends F, Kesecioglu J (2001). Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. *Intensive Care Med* 27, 1825-1829
- Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, Ingerslev J, Sørensen B (2009). Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. *J Thromb Haemost* 7, 795-802
- Gabali A, Jazearly T, Ramchandren R, Bluth MH (2014). Applications of coagulation testing and methodology in the trauma patient. *Research and Reviews: Journal of Medical and Health Sciences* 3, 1-4
- Gan TJ (2011). Colloid or crystalloid: any differences in outcomes? *IARS Review Course Lectures*, 7-12
- Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012). Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. *Crit Care* 16, R94
- Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, Oswald E, Salner E, Frischhut B, Schobersberger W (2002). The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. *Anesth Analg* 95, 858-865

- Kamal AH, Tefferi A, Pruthi RK (2007). How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. *Mayo Clin Proc* 82, 864-873
- Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P (2008). The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. *Anesth Analg* 107, 382-390
- Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P (2001). Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. *Anesth Analg* 92, 855-862
- Lenting PJ, Christophe OD, Denis CV (2015). von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. *Blood* 125, 2019-2028
- Mills GH (2007). Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? *Br J Anaesth* 98, 157-159
- Muralidhar K, Garg R, Mohanty S, Banakal S (2010). Influence of colloid infusion on coagulation during off-pump coronary artery bypass grafting. *Indian J Anaesth* 54, 147-153
- Myburgh JA and Mythen MG (2013). Resuscitation fluids. *The New England Journal of Medicine* 369, 1243-1251
- Ng KF, Lam CC, Chan LC (2002). In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. *Br J Anaesth* 88, 475-480
- Peyvandi F, Garagiola I, Baronciani L (2011). Role of von Willebrand factor in the haemostasis. *Blood Transfus* 9, s3-s8
- Reininger AJ (2008). Function of von Willebrand factor in haemostasis and thrombosis. *Haemophilia* 14, 11-26
- Rittoo D, Gosling P, Simms MH, Smith SR, Vohra RK (2005). The effects of hydroxyethyl starch compared with gelofusine on activated endothelium and the systemic inflammatory response following aortic aneurysm repair. *Eur J Vasc Endovasc Surg* 30, 520-524
- Ruttmann TG, James MF, Finlayson J (2002). Effects on coagulation of intravenous crystalloid or colloid in patients undergoing peripheral vascular surgery. *Br J Anaesth* 89, 226-230
- Sadler JE (2009). Low von Willebrand factor: sometimes a risk factor and sometimes a disease. *Hematology Am Soc Hematol Educ Program*, 106-112
- Wilson DD (2007). *McGraw-Hill Manual of Laboratory and Diagnostic Tests* 1st Edition, New York, McGraw-Hill Education

# FOLIA MEDICA INDONESIA

PUBLISHED BY  
THE CENTER FOR MEDICAL SCIENCE COMMUNITY  
FACULTY OF MEDICINE, UNIVERSITAS AIRLANGGA

p-issn 2355-8393  
e-ISSN 2599-056X  
Accredited no. 2/E/KPT/2015

[HOME](#) [ABOUT](#) [LOGIN](#) [REGISTER](#) [SEARCH](#) [CURRENT](#) [ARCHIVES](#)

[Home](#) > [About the Journal](#) > [Editorial Team](#)

## EDITORIAL TEAM

### EDITOR-IN CHIEF

[Ni Made Mertaniasih](#), Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

### DEPUTY EDITORS

[Muhammad Miftahussurur](#), Universitas Airlangga; Baylor College Medicine, Houston, US, Indonesia

### EDITORIAL BOARD

[Arend Frederik Bos](#), Division Neonatology, Faculty of Medical Sciences, University of Groningen, Netherlands

[Hiroaki Kimura](#), Department of Physical Medicine and Rehabilitation, Hiroshima University Hospital, Japan

[Jitti Hanprasertpong](#), Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

[Anucha Thatrimontrichai](#), Prince of Songkla University, Thailand

[Surasak Sangkhathat](#), Pediatric Surgery Unit, Department of Surgery, Prince of Songkla University, Songkhla, Thailand

[Delvac Oceandy](#), University of Manchester, Manchester, United Kingdom

[Brahmaputra Marjadi](#), Western Sydney University, Penrith, Australia

[aryati aryati](#), Airlangga University, Indonesia

[Viskasari Pintoko Kalanjati](#), Department of Anatomy and Histology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

[Irwanto Irwanto](#), Universitas Airlangga, Indonesia

[Wihasto Suryaningtyas](#), Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Asra Al Fauzi](#), Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Azimatul Karimah](#), Department of Psychiatry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Lucky Prasetiowati](#), Department of Anatomy & Histology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Bambang Purwanto](#), Department of Medical Physiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

### MANAGING EDITOR

[Ahmad Suryawan](#), Department of Pediatrics, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

### PRODUCTION EDITORS

[Moch. Zuhdy](#), Center for Medical Science Community, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Athfiyatul Fatati](#), Center for Medical Science Community, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

[Alviana Nur Afifah](#), Center for Medical Science Community, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

#### Instruction for Author

[How to Submit](#)

[Guidelines for Authors](#)

[Online Submission](#)

[Document Template](#)

[Disclaimer](#)

#### Journal Policy

[Focus and Scope](#)

[Publication Ethics](#)

[Article Processing Charge](#)

[Editorial Team](#)

[Peer Reviewers](#)

[Peer Review Process](#)

[Open Access Statement](#)

[Plagiarism Check](#)

[Archiving](#)

[Copyright](#)

[Contact](#)

[Old Website](#)

#### OPEN JOURNAL SYSTEMS

##### Journal Help

#### USER

Username

Password

Remember me

#### NOTIFICATIONS

[View](#)

[Subscribe](#)

#### JOURNAL CONTENT

Search

Search Scope

All

Browse

[By Issue](#)

[By Author](#)

